ArticleJournal of translational medicine2026
7,7"-dimethoxyagastisflavone induced MYCN/MYBL2-dependent apoptosis and metabolism reprogramming in Sonic Hedgehog medulloblastoma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMedulloblastoma (MB) is the most common malignant pediatric brain cancer. Patients diagnosed with Sonic Hedgehog (SHH) MB typically exhibit highly metastatic tumors and have an unfavorable prognosis. 7,7”-Dimethoxyagastisflavone (DMGF), a biflavonoid compound, isolated from needles of Taxus x media cv. Hicksii. The purpose of this study is to explore the potential targets of SHH MB and the therapeutic effects of DMGF in SHH MB.
methodsRNA sequencing was used to analyze malignancy-related genes in SHH MB patient tumors. Experiments on cytotoxicity, apoptosis, cell cycle, migration, F-actin assembly, EMT, metabolite changes, and macrophage polarization demonstrated that DMGF induced cell death by inhibiting MYCN and MYBL2. The therapeutic effect of DMGF was studied in MB orthotopic xenograft mice. Three-dimensional images exhibited the brain-wide distribution of MB tumors. Patient-derived MB cells were utilized to demonstrate the potential of DMGF as a future therapy.
resultsTaiwanese SHH MB patients with high MYCN and MYBL2 expression had lower 5-year overall survival, suggesting that MYCN and MYBL2 are related to the malignancy. DMGF decreased MYCN and MYBL2 expression, which arrests the cell cycle, induces apoptosis, impedes cell migration, and inhibits the EMT response. DMGF disrupted redox balance and inhibited energy-related metabolism in SHH MB cells. DMGF-induced macrophage polarization that built an antitumor microenvironment. The inhibitory effects of DMGF on MYCN/MYBL2 were also confirmed in patient-derived MB cells.
conclusionInhibiting MYCN and MYBL2 is the key to DMGF’s anti-tumor effects. These findings suggest the potential of DMGF as a future chemotherapeutic agent for MB treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.